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Uusi Käypä hoito -suositus mahdollistaa keliakiadiagnoosin asettamisen ilman ohutsuolen koepaloja 
kudostransglutaminaasivasta-aineiden ollessa >10x kynnysarvon (upper limit of normal, ULN) yhdessä 
positiivisten endomysiumvasta-aineiden (EmA) kanssa. Haasteena on markkinoilla olevilta useilta kaupallisilta 
testeiltä puuttuva standardisointi. Tutkimme, miten luotettavia erilaiset kaupalliset testit ovat serologiaan 
perustuvassa keliakiadiagnostiikassa aikuisilla. 
Tutkimuskohortti muodostui kahdesta keliakian ennakkotodennäköisyydeltään eroavasta ryhmästä. 
Korkean riskin tutkittavilla (n=239) potilailla oli vahva kliininen epäily ja kohtalaisen riskin ryhmässä (n=597) 
sukuriski keliakialle. Seeruminäytteet testattiin neljällä kaupallisella vasta-ainetestillä (Celikey, Orgentec, 
Eurospital ja Inova). Diagnoosit varmistettiin ohutsuolibiopsialla ja joissakin tapauksissa erikoistutkimuksilla. 
Lisäksi kaikilta määritettiin keliakiaan liittyvä HLA-DQ2/8 genotyyppi sekä EmA. 
Kliinisessä ryhmässä kaikkiaan 137 (57%) ja perheryhmässä 85 (14%) tutkimushenkilöä saivat 
keliakiadiagnoosin. Positiivinen ennustearvo (PPV) oli 100% (95% luottamusväli 78.1% – 100%) kaikille 
neljälle vasta-ainetestille molemmissa ryhmissä käytettäessä raja-arvoa 10x ULN. Ensimmäiset negatiiviset 
keliakialöydökset positiivisilla testituloksilla ilmaantuivat testistä riippuen kliinisessä ryhmässä välillä 1.0x – 
5.1x ULN ja perheryhmässä välillä 1.3x – 4.9x ULN. Käyttämällä testien omia raja-arvoja (1x ULN) PPV vaihteli 
välillä 83.6 – 100%. 
Tutkimus osoitti kaikkien neljän vasta-ainetestin olevan varsin luotettavia käytettäessä nykyistä 10x ULN 
kriteeriä, mikä tukee uudistetun Käypä hoito -suosituksen toimivuutta keliakian diagnostiikassa. Etenkin osa 
testeistä toimi hyvin myös selvästi matalammilla ULN -kertoimilla. Mikäli löydös varmistetaan, se mahdollistaisi 
tähystystutkimusten vähentämisen entuudestaan. 
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1. ABSTRACT 
 
Non-biopsy diagnosis of celiac disease is possible in children with anti-transglutaminase 2 
antibodies (TGA) > 10× the upper limit of normal (ULN) and positive anti-endomysial antibodies 
(EMA). Similar criteria have been suggested for adults, but evidence with different TGA assays is 
scarce. We compared the performance of four TGA tests in the diagnosis of celiac disease in cohorts 
with diverse pre-test probabilities. Serum samples from 836 adults with either clinical suspicion or 
family risk of celiac disease were tested with four commercial TGA assays, EmA and celiac disease-
associated genetics. The diagnosis was set based on duodenal lesion or, in some cases, using 
special methods. 137 (57%) patients with clinical suspicion and 85 (14%) of those with family risk 
had celiac disease. Positive predictive value (PPV) for 10× ULN was 100% in each TGA test. The 
first non-diagnostic investigations were encountered with ULN 1.0×–5.1× in the clinical cohort and 
1.3×–4.9× in the family cohort, respectively. Using the assays’ own cut-offs (1×ULN) the PPVs 
ranged 84–100%. Serology-based diagnosis of celiac disease was accurate in adults using different 
commercial kits and pre-test probabilities using 10× ULN. The results also suggest that the ULN 
threshold for biopsy-omitting approach could be lower. 
  
2. INTRODUCTION 
 
The estimated true prevalence of celiac disease is 1–3% [1,2], emphasizing the importance of 
efficient and practical diagnostic strategy for this common condition. At the same time, diagnosis of 
a life-long disease must be based on solid evidence. This has long been achieved by demonstrating 
characteristic mucosal damage in duodenal biopsy, but such a histology-based approach is invasive 
and technically challenging [3,4]. Together with the high specificity of modern serological tests, the 
aforesaid challenges have led to the introduction of new pediatric guidelines for diagnosing celiac 
disease, enabling a non-biopsy diagnosis in selected children with anti-transglutaminase 2 
antibodies (TGA) > 10× the upper limit of normal (ULN) and positive anti-endomysial antibodies 
(EmA) [5]. 
It has been suggested that the biopsy-omitting approach could also be extended to adult patients 
[6,7] and, supporting this, we recently reported a positive predictive value (PPV) of 100% for the 
serological criteria in adults with variable pre-test probabilities for celiac disease [8]. The results, 
however, were obtained utilizing only one TGA assay and thus cannot be directly generalized due 
to a lack of standardization between the commercial tests. In fact, the artificial 10× ULN cutoff and 
requirement of EmA were introduced mainly to overcome the variation in the diagnostic performance 
of the TGA-based tests [5]. So far only a few-and exclusively pediatric-studies have directly 
compared the accuracy of non-biopsy approach for celiac disease with different TGA assays [9]. 
We investigated this issue by applying four widely used commercial TGA tests in two large and 
well-defined cohorts of adults with either clinical suspicion (high pre-test probability) or family risk 
(moderate pre-test probability) of celiac disease. 
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3. MATERIALS AND METHODS 
 
3.1 Patients and Study Design 
The study was conducted in the Celiac Disease Research Center, Tampere University and 
Tampere University Hospital. The patients were collected from among 836 adults, who were further 
categorized into two sub-cohorts based on assumed pre-test probability for celiac disease (Figure 
1). Exclusion criteria were age < 18 years and previous celiac disease diagnosis or otherwise 
restricted dietary gluten consumption. 
The “clinical cohort” with expected high pre-test probability for celiac disease included 239 
subjects referred from primary care due to various gastrointestinal and/or extraintestinal symptoms 
suggestive of celiac disease. They might have been tested previously for celiac disease with 
serology. All subjects underwent esophagogastroduodenoscopy (EGD) with systematic duodenal 
sampling (Figure 1), and also participated in research projects that included sampling and storing of 
sera and whole blood that were subsequently used for testing the studied TGA assays, EmA and 
celiac disease-associated genetics. 
The “family cohort” with presumed moderate pre-test probability for celiac disease consisted of 
597 adults, with one or more previously affected relative(s), recruited via newspaper announcements 
and with the help of the Finnish Celiac Society [10]. They underwent sampling and storing of blood 
for serological and other celiac disease-related measurements similarly to the subjects in the clinical 
cohort. The option for EGD and biopsies was offered to all subjects with suspicion of celiac disease 
according to their serology results (Figure 1). The endoscopies were conducted either in Tampere 
University Hospital or in other local health care units having experience in celiac disease diagnostics. 
 
 
 
 
Figure 1. Flowchart of the study. Clinical cohort (Panel A) comprises subjects referred from primary care due 
to suspicion celiac disease (CD). All cases underwent duodenal sampling. Some of the patients with 
inconclusive histology received the diagnosis in a re-biopsy after one year (“Gluten challenge”). In a subset, 
the diagnosis was set on the basis of special investigations and clinical, serological, and histological 
response to gluten-free diet (“Special methods”). The family cohort (Panel B) includes subjects with ≥1 
relative with celiac disease. Only seropositive subjects were referred for further investigations. *Refusal, self-
initiated gluten reduction, and exitus before biopsy. 
 
 
3.2 Ethics 
The study protocol and patient enrollment were approved by the regional ethics committee of 
Pirkanmaa Hospital District (ETL R05183, accepted 6th February 2007). All participants gave written 
informed consent. The manufacturers of the TGA assays studied had no role in study design, data 
analysis or interpretation or writing of the manuscript. The study protocol conforms to the ethical 
guidelines of the 1975 Declaration of Helsinki. 
 
3.3 Serological and Genetic Testing 
Four different commercial enzyme-linked immunosorbent assays (ELISA) were utilized to test 
IgA-class TGA, including Celikey (Phadia, Freiburg, Germany), Inova (QUANTA Lite h-tTG, Inova 
Diagnostics, San Diego, CA, USA), Orgentec (ORG 540A, Orgentec Diagnostika, Mainz, Germany), 
and Eurospital (Eu-tTG, Trieste, Italy). The cut-offs used for seropositivity were 5 U/mL, 20 U/mL, 10 
U/mL and 10 U/mL respectively. The corresponding 10 × ULN were therefore 50 U/ml (Phadia), 200 
U/mL (Inova), 100 U/mL (Orgentec), and 100 U/mL (Eurospital), respectively. These were also the 
upper limit of measuring range for Inova and Eurospital, while those for Phadia and Orgentec were 
101 U/mL and 200 U/mL, respectively. All assays studied had passed the appropriate quality controls 
as requested in the non-biopsy guidelines [5]. 
EmA were determined in-house with indirect immunofluorescence using human umbilical cord 
as an antigen [11,12]. A serum dilution 1: ≥5 was considered positive and further diluted until 
negative or up to 1:4000. 
The celiac disease-associated human leucocyte antigen (HLA) genotypes encoding DQ2 and 
DQ8 molecules on antigen presenting cells were studied from the whole blood samples as described 
elsewhere [8,10]. 
 
3.4 Histology 
A minimum of four representative forceps biopsies were taken from the duodenum during each 
EGD. The paraffin-embedded samples were cut, stained with hematoxylin-eosin and studied under 
a light microscope. Only representative and carefully orientated mucosal sections were included in 
the histopathological analysis [3]. The majority of celiac disease diagnoses were based on the 
demonstration of villous atrophy and crypt hyperplasia, equivalent for Marsh 3 lesion [3,13]. 
In case of milder non-diagnostic lesions, participants were offered additional investigations. 
Some of the subjects continued on a gluten-containing diet for one year (“gluten challenge”), after 
which new biopsies were taken and the diagnosis was confirmed if Marsh 3 was present. In a 
subgroup of patients with non-diagnostic lesions, special diagnostic methods were applied. These 
included quantitative determination of villous height-crypt depth ratio (VH/CrD) from paraffin sections 
[3], measurement of mucosal CD3+ (<37 cells/mm) and γδ+ (<4.3 cells/mm) intraepithelial 
lymphocytes (IEL), and celiac disease-specific IgA deposits from frozen sections [12,14,15]. The 
subjects started a one-year trial on gluten-free diet (GFD), after which the baseline investigations 
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were repeated, and the diagnosis was set on the basis of positive EmA and IgA deposits and 
increased CD3+ and γδ+ IELs at baseline and clinical, serological and histological response to the 
GFD. 
Some patients with non-diagnostic duodenal histology had a bullous rash indicative of dermatitis 
herpetiformis (DH), in which case the diagnosis was confirmed by demonstrating granular IgA 
deposits in a skin biopsy [16]. 
 
3.5 Statistics 
SPSS® Statistics version 25 (IBM, Armonk, NY, USA) was used for statistical analyses. The data 
are presented either as number of cases and percentages or as medians with ranges as appropriate. 
PPV was calculated by dividing the number of true positives (celiac disease) by all test positives 
(PPV = true positives/[true positives +false positives]). The 95% confidence intervals (CI) for PPV 
are also given. As a sensitivity analysis, PPV were calculated also considering as true positives only 
subjects whose celiac disease diagnosis was based on morphological lesion (Marsh 3) in the 
duodenum (“worst case scenario”). All data were analyzed blinded in collaboration with a medical 
statistician (H. H.). 
  
4. RESULTS 
 
 
Altogether 125 subjects in the clinical cohort had a diagnostic duodenal lesion in either the 
primary EGD or after prolonged gluten consumption, and a further 12 received the diagnosis based 
on special investigations (Figure 1A, Table S1). Correspondingly, 85 subjects in the family cohort 
received the diagnosis either directly or after additional investigations (Figure 1B, Table S1). 
The two study cohorts had comparable median ages, while there was a female predominance 
in the clinical cohort compared with the almost even gender distribution in the family cohort (Table 
1). By definition, 100% of the subjects in the family cohort had relative(s) with celiac disease, while 
the corresponding proportion in the clinical cohort was approximately one-fifth. All participants 
receiving the diagnosis had HLA DQ2/8 genotype consistent with celiac disease (Table 1).  
The overall frequency of seropositivity using manufacturer’s cut-offs for the TGA assays tested 
ranged from 48.5% to 62.3% in the clinical cohort and from 15.4% to 43.0% in the family cohort. The 
corresponding numbers in those receiving a celiac disease diagnosis were 84.7–96.6% and 76.5–
98.8% (Table 1). 
 
Table 1. Baseline characteristics and positivity for the serological assays tested in the two study cohorts. 
  Clinical cohort    Family cohort  
 
All subjects 
n=239 
 
Celiac disease  
n=137 
 
All subjects 
n=597 
 
Celiac disease 
n=85 
 %  %  %  % 
Baseline data        
Age, median (range), yr 45 (17-83)  45 (18-74)  48 (18-96)  44 (18-80) 
Females 72.8  79.6  53.4  50.6 
Celiac disease in relative 21.1  25.8  100  100 
HLA DQ2/DQ8 82.8  100  74.4  100 
TGA positivity        
Celikey 48.5  84.7  15.4  76.5 
Orgentec 51.8  90.8  18.6  88.8 
Eurospital 55.5  91.6  23.8  96.3 
Inova 62.3  96.6  43.0  98.8 
EmA positivity 51.5  89.8  19.3  98.8 
Data was available on >85% of the subjects in each category.  EmA, endomysium antibodies; HLA, human leukocyte 
antigen; TGA, transglutaminase 2 antibodies 
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When applying a cut-off 10× ULN, all four TGA assays showed a PPV of 100% in both clinical 
(95% CIs from 88.0–100% to 92.0–100%) and family (95% CIs from 78.1–100% to 87.0–100%) 
cohorts (Table 2). With the pre-defined 1× ULN cut-offs the corresponding PPVs ranged in clinical 
cohort from 83.6% to 100% (95% CIs from 76.0–89.2% to 96.0–100%) and in family cohort from 
90.3% to 100% (95% CIs from 82.0–95.2% to 90.7–99.9%), respectively (Table 2). The ULNs 
calculated by exploiting the highest positive TGA value without celiac disease diagnosis for each 
assay ranged from 1.0× to 5.1× in the clinical cohort and from 1.3× to 4.9× in the family cohort (Table 
3).  
Table 2. Positive predictive values (PPV) of the four study tests for celiac disease in the clinical and family 
cohorts. 
 ≥10× ULN a ≥1× ULN a 
 
Positive 
Subjects 
(n) 
Celiac 
Disease 
(n) 
PPV 
(%) 
95% CI 
(%) 
Positive 
Subjects 
(n) 
Celiac Disease 
(n) 
PPV 
(%) 
95% CI 
(%) 
Clinical 
cohort 
        
Celikey 56 56 100 92.0–100 116 116 100 96.0–100 
Orgentec 36 36 100 88.0–100 113 108 95.6 89.5–98.4 
Eurospital 51 51 100 91.3–100 121 109 90.1 83.0–94.5 
Inova 54 54 100 91.7–100 134 112 83.6 76.0–89.2 
Family cohort         
Celikey 18 18 100 78.1–100 66 65 98.5 90.7–99.9 
Orgentec 26 26 100 84.0–100 78 72 92.3 83.4–96.8 
Eurospital 33 33 100 87.0–100 84 78 92.9 84.5–97.1 
Inova 21 21 100 80.8–100 93 84 90.3 82.0–95.2 
a Celikey 5.0 U/mL; Inova 20 U/mL; Orgentec 10 U/mL; Eurospital 10 U/mL. CI, confidence interval; ULN, upper 
limit of normal. 
 
Table 3. Highest positive transglutaminase 2 antibody value without celiac disease diagnosis for each study assay 
tested. Above these values the positive predictive value was 100% for all assays. 
  Clinical cohort    Family cohort  
 Value, U/ml xULNa  Value, U/ml xULNa 
Celikey 4.8 1.0  6.6 1.3 
Orgentec 32 3.2  24 2.4 
Eurospital 38 3.8  38 3.8 
Inova 102 5.1  98 4.9 
aCelikey 5.0 U/ml; Inova 20 U/ml; Orgentec 10 U/ml; Eurospital 10 U/ml 
ULN, upper limit of normal 
 
Assuming that only cases with Marsh 3 at any time in the duodenal biopsy or confirmed DH 
were correctly diagnosed, the PPV for 10× ULN remained 100% in all tests in the family cohort but 
dropped to 98.1% with QUANTA Lite and to 98.0% with Eurospital in the clinical cohort (Table S2). 
The corresponding figures for 1× ULN were 76.9–94.8% in the clinical cohort and 88.2–97.0% in the 
family cohort (Table S2). For Celikey and Orgentec, in which the PPV for 10x ULN remained 100% 
even with “worst case scenario”, the highest values for negative biopsy were 9.6× and 5.3× ULN 
respectively.  
EmA were positive in 89.8% and 98.8% of those with celiac disease in the clinical and family 
cohorts, respectively (Table 1). Altogether, EmA was positive in 95.7% of the Celikey, 90.1% of the 
Orgentec, 78.5% of the Eurospital, and 54.7% of the Inova positive patients; for those who were 
eventually diagnosed with celiac disease the corresponding figures were 95.6%, 95.0%, 93.6%, and 
93.4%, respectively. One subject with TGA >10× ULN in all four tests was EmA negative, as were 
four subjects with only Eurospital or Inova 10× ULN. All EmA positive participants had HLA DQ2/8. 
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5. DISCUSSION 
 
 
All four commercial TGA assays tested here demonstrated a PPV of 100% for celiac disease 
when applying the 10× ULN cutoff as specified by the European Society for Paediatric 
Gastroenterology Hepatology and Nutrition (ESPGHAN) [5]. The excellent accuracy of the serology-
based criteria observed here, if used as recommended, is in line with the majority of recent 
retrospective and prospective pediatric studies [9,17–20]. Together with the previous single-assay 
study by us and some similar reports by other research groups [6,7,21–23], these findings provide 
further evidence that the biopsy-sparing guidelines could also be applied to adult celiac disease 
patients. 
Only a limited number of studies have compared the performance of two or more TGA assays 
in the serological diagnosis of celiac disease in the same patients; in fact, to the best of our 
knowledge, such comparisons have been reported only in children [7,9,22,24]. A few previous adult 
studies have nevertheless utilized two TGA assays in separate cohorts and the result can thus be 
indirectly compared with our findings [7,22]. Zanini et al. [22] found 5×ULN to be 100% specific for 
celiac disease with Eurospital and Celikey. However, the ULNs used were 7 U/mL and 16 U/mL for 
Eurospital (two groups) and 8 U/mL for Celikey, and thus differed from those used here. Efthymakis 
et al. [7] observed PPVs of 96% and 100% for two tests with 10×ULN, but the assays used were not 
reported. In children, Werkstetter et al. [9] tested the ESPGHAN criteria meticulously with eight TGA-
IgA assays, including Celikey, Inova and Eurospital, and found PPVs of 99.8–100% for >10× ULN. 
In addition, Rozenberg et al. [24] reported PPVs of >99% for four automated TGA analyzers and 
98% for one ELISA kit. 
Nevertheless, lower PPVs for non-biopsy approach have also been reported [25,26]. These 
discrepancies may, at least partially, be attributable to methodological differences, including e.g., 
variable use of ULN cutoff for a given assay, lack of confirmatory EmA testing, and challenges in 
applying histology as the reference standard [3,9]. A further explanation for inconclusive histology 
could be early developing celiac disease presenting with only mild/patchy mucosal changes or 
extraintestinal form with no apparent intestinal lesion [5,12,16], as also demonstrated here in those 
who developed diagnostic lesion only after gluten challenge or who had DH. A subgroup of our 
patients was also diagnosed with a so-called mild enteropathy celiac disease [12,27]. This could be 
criticized, but they were rigorously investigated with sophisticated diagnostic methods and 
demonstrated objectively measured treatment response, strongly supporting the presence of celiac 
disease. Moreover, even if they had all been considered to be non-celiacs, the PPVs for 10× ULN 
would still have remained excellent. 
Of note, performance of the TGA assays was not affected by the assumed pre-test probability 
for celiac disease, as they worked equally well in both study cohorts. This is in line with our previous 
single-assay study [8] and dispels the fears that lower pre-test probability for the disease, particularly 
in screen-detected individuals, would lead to poorer diagnostic accuracy [6,28]. In fact, results of the 
present and previous studies indicate that serology actually correlates better with the degree of 
histological lesion than the severity or nature of the symptoms [29–32]. Likewise, in recent studies 
the non-biopsy criteria have been equally reliable in symptomatic and asymptomatic children 
[19,25,33] and ESPGHAN now allows a non-biopsy approach regardless of the clinical presentation 
[5]. 
There was also excellent compatibility between TGA values >10× ULN and EmA positivity. This 
is important, as EmA is considered as the serological reference test that can be utilized to control for 
the performance variation of the TGA assays [5]. This finding also indicate that this laborious 
confirmatory step which is not feasible in all centers could be omitted in case of well-validated TGA 
tests with values >10× ULN. EmA could nevertheless remain useful in borderline cases. In contrast, 
as also reported in other recent studies [8,9,19], measurement of celiac disease-associated HLA did 
not provide additional benefits. Accordingly, HLA is no longer required by ESPGHAN [5] although it 
can be valuable in the differential diagnostics of seronegative duodenal lesion [34]. 
Depending on the TGA assay, lower than 10× ULN (1.0×–5.1×) also showed 100% PPV for 
celiac disease, and similar findings have been reported in a few earlier studies [22,35]. This suggests 
that the proportion of subjects eligible for non-biopsy approach could be increased. The lack of 
standardization between the TGA tests and their different diagnostic performances nevertheless 
complicates this issue. As also seen here, some of the assays are clearly intended more as sensitive 
screening tests whereas others have higher specificity even with low positive values. One possible 
option might be serial testing with two TGA assays, but at this point the scarcity of evidence makes 
it challenging to decide optimal combination. EmA confirmation could still be useful in these 
circumstances, particularly if aiming to lower the required ULN factor or when testing a new TGA 
combination. On the other hand, the chosen strategy should not be too complicated for routine 
clinical use. More studies designed to investigate specifically this issue are urgently needed. 
 
5.1 Strengths and Weaknesses 
The main strengths of our study were the use of two large and well-defined cohorts of patients 
with different pre-test probabilities for celiac disease [3,12]. We were also able to exploit 
sophisticated diagnostic methods in inconclusive cases, although special investigations were not 
conducted systemically on all participants. There were also limitations. First, EGDs were not 
centralized to a single hospital, although this should not be a major source of bias as celiac disease 
diagnostics are harmonized throughout Finland [36]. Second, some of the patients in the clinical 
cohort had already been tested for TGA before their referral, but significant bias is again unlikely 
since the results were comparable with those of the previously untested family cohort. Finally, one 
more potential shortcoming was that we did not control for a possible reduction of the dietary gluten 
while awaiting the biopsy. 
 
5.2 Conclusions 
We found the serology-based diagnosis of celiac disease in adults to be accurate with different 
commercial TGA assays in individuals with variable pre-test probabilities, further supporting the 
transition towards a less invasive diagnostic approach also after childhood. The results also suggest 
that, at least in well-validated TGA assays, the specified cut-off for non-biopsy approach could be 
lowered, but more research on this issue is needed. 
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